Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology

 
• By Eleanor Malone

Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.

2017 new year concept, chicken silhouette in sunrise
Sangamo heralds new dawn for engineered Tregs • Source: Shutterstock

More from Deals

More from Business